Company intelligence

AEON Biopharma

As of September 4, 2026, AEON Biopharma had a market capitalization of $12.01M (stockanalysis.com).

Clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.

BiotechPublic · AEONIrvine, California, USAFounded 2013Public company
Last verified Sep 4, 2026

AEON Biopharma at a glance

As of
Market cap
$12.01M[1]
September 2026
Headquarters
Irvine, California, USA[2]
  1. [1] Market cap: stockanalysis.com, September 4, 2026
  2. [2] Headquarters: SEC EDGAR (AEON Biopharma 10-K cover page) (retrieved March 30, 2026)

Is something wrong on this page?

Company Snapshot

AEON Biopharma is a biotech company, based in Irvine, California, USA, founded 2013.

Recent changes

  1. Sep 4, 2026First reported market cap: $12.01M stockanalysis.com
  2. Jul 9, 2026AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline Pulse story

Latest Pulse

  1. AEON Biopharma, Mobix Labs S-1 Filings Test a Thin PipelineAEON Biopharma filed a fresh S-1 for a biosimilar program while Mobix Labs amended its filing disclosing a going-concern warning -- a reminder this week's IPO pipeline is mostly small-cap, not AI infrastructure.→
  2. This Week's Quiet IPO Calendar Is the Real StoryBeyond SK Hynix's $28-29 billion Nasdaq debut, this week's US IPO calendar is nearly empty -- a sharp contrast to June's run of SpaceX, Cerebras and Lime, and a sign the pipeline is thinner than headline enthusiasm suggests.→

Coverage Timeline

newest first
  1. Jul 9, 2026IPOAEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline→

All Coverage

IPO
AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline
Illustration for: AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline
IPO

AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline

AEON Biopharma filed a fresh S-1 for a biosimilar program while Mobix Labs amended its filing disclosing a going-concern warning -- a reminder this week's IPO pipeline is mostly small-cap, not AI infrastructure.

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

AEON Biopharma FAQ

What is AEON Biopharma's market cap?

AEON Biopharma's market capitalization was $12.01M as of September 4, 2026, according to stockanalysis.com.

Is AEON Biopharma publicly traded?

Yes. AEON Biopharma trades under the ticker AEON, with a market cap of $12.01M (September 4, 2026, stockanalysis.com).

Where is AEON Biopharma headquartered?

AEON Biopharma is headquartered in Irvine, California, USA, according to SEC EDGAR (AEON Biopharma 10-K cover page).

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·